X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs NOVARTIS - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA NOVARTIS GSK PHARMA/
NOVARTIS
 
P/E (TTM) x 60.0 346.4 17.3% View Chart
P/BV x 11.8 17.1 69.0% View Chart
Dividend Yield % 2.1 1.7 123.9%  

Financials

 GSK PHARMA   NOVARTIS
EQUITY SHARE DATA
    GSK PHARMA
Mar-16
NOVARTIS
Mar-16
GSK PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs3,850982 392.1%   
Low Rs2,966556 533.2%   
Sales per share (Unadj.) Rs332.3252.9 131.4%  
Earnings per share (Unadj.) Rs44.362.1 71.3%  
Cash flow per share (Unadj.) Rs47.263.3 74.6%  
Dividends per share (Unadj.) Rs50.0010.00 500.0%  
Dividend yield (eoy) %1.51.3 112.8%  
Book value per share (Unadj.) Rs202.7363.6 55.8%  
Shares outstanding (eoy) m84.7031.96 265.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x10.33.0 337.2%   
Avg P/E ratio x76.912.4 621.6%  
P/CF ratio (eoy) x72.212.2 593.8%  
Price / Book Value ratio x16.82.1 794.7%  
Dividend payout %112.916.1 701.4%   
Avg Mkt Cap Rs m288,64324,580 1,174.3%   
No. of employees `0004.60.8 613.2%   
Total wages/salary Rs m4,4341,801 246.2%   
Avg. sales/employee Rs Th6,104.510,748.9 56.8%   
Avg. wages/employee Rs Th961.62,395.2 40.1%   
Avg. net profit/employee Rs Th813.72,641.1 30.8%   
INCOME DATA
Net Sales Rs m28,1488,083 348.2%  
Other income Rs m1,218829 146.9%   
Total revenues Rs m29,3668,913 329.5%   
Gross profit Rs m4,774234 2,038.3%  
Depreciation Rs m24837 675.7%   
Interest Rs m02 0.0%   
Profit before tax Rs m5,7441,025 560.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m261,696 1.5%   
Tax Rs m2,018752 268.4%   
Profit after tax Rs m3,7521,986 188.9%  
Gross profit margin %17.02.9 585.3%  
Effective tax rate %35.173.4 47.9%   
Net profit margin %13.324.6 54.2%  
BALANCE SHEET DATA
Current assets Rs m21,46212,678 169.3%   
Current liabilities Rs m10,5362,433 433.1%   
Net working cap to sales %38.8126.7 30.6%  
Current ratio x2.05.2 39.1%  
Inventory Days Days6833 206.9%  
Debtors Days Days1622 73.0%  
Net fixed assets Rs m4,71769 6,816.6%   
Share capital Rs m847160 530.0%   
"Free" reserves Rs m16,30811,460 142.3%   
Net worth Rs m17,17111,621 147.8%   
Long term debt Rs m160-   
Total assets Rs m30,62014,400 212.6%  
Interest coverage xNM570.5-  
Debt to equity ratio x00-  
Sales to assets ratio x0.90.6 163.8%   
Return on assets %12.313.8 88.8%  
Return on equity %21.917.1 127.9%  
Return on capital %33.623.6 142.4%  
Exports to sales %00.7 1.9%   
Imports to sales %15.118.6 81.0%   
Exports (fob) Rs m460 6.6%   
Imports (cif) Rs m4,2371,503 282.0%   
Fx inflow Rs m519186 278.6%   
Fx outflow Rs m8,3201,821 456.9%   
Net fx Rs m-7,801-1,635 477.3%   
CASH FLOW
From Operations Rs m1,3862,531 54.7%  
From Investments Rs m5,010-8,270 -60.6%  
From Financial Activity Rs m-6,383-386 1,655.0%  
Net Cashflow Rs m12-6,125 -0.2%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 75.0 67.6%  
Indian inst/Mut Fund % 10.2 2.0 510.0%  
FIIs % 23.8 1.6 1,487.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 21.5 71.6%  
Shareholders   102,036 41,647 245.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 17, 2017 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - VENUS REMEDIES COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS